Back to search results

Radiation Therapy for Inoperable Breast Cancer

This study is looking at two types of radiation therapy for women with breast cancer that cannot be removed by surgery or for those who choose not to have surgery. The treatments are called Whole Breast Radiation with Simultaneous Integrated Boost (WB-SIB). One type targets the breast tumor, and the other targets both the breast tumor and nearby lymph nodes (small glands that are part of your immune system). The goal is to see how safe these radiation treatments are over 12 months. You may be able to join if you have invasive breast cancer (T1-T4, N0-2, M0-1 stages) that a doctor has determined cannot be surgically removed, or if you prefer not to have surgery. This study is planning to enroll 30 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 30 women.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Treatment safety will be measured for 12 months after the radiation therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07122713

Definitive Radiation Therapy for Inoperable Breast Cancer

Recruiting
NAAges 18+InterventionalTreatment
Alexander Stessin
~30 participants
Updated 2025-12-17 on ClinicalTrials.gov
What's tested:Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumorWhole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor and ipsilateral axillary lymph nodes

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Treatment Safety
Measured over 12 months

Conditions

Breast Cancer
Breast Adenocarcinoma

Explore related trials

Breast Carcinoma

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Alexander Stessin, MD PhD · PRINCIPAL_INVESTIGATOR · Stony Brook University Hospital

Who to contact

Caterina Stony Brook Cancer Center Clinical Trials
[email protected]
631-728-7425
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Biopsy proven invasive carcinoma of the breast, either lobular, ductal and/or no special type
T1-T4, N0-2, M0-1 invasive breast carcinoma by radiological or clinical criteria
Cancer is deemed unresectable, or the patient is a poor surgical candidate as determined following evaluation by a surgeon, or patient declines surgery.
Life expectancy \> 6 months
Negative pregnancy test at the time of start of treatment in any female of reproductive age

Exclusion

Concurrent systemic therapy (except for endocrine therapy, HER2-targeted therapy, or immunotherapy which are permitted)
Prior radiation to ipsilateral breast or regional nodes
Inability to receive study treatment planning and treatment secondary to body habitus

What this trial measures

  • Treatment Safety12 months

    Incidence of physician-assessed treatment-related toxicity ≥ Grade 4 events, as defined using CTCAE 5.0